The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae

被引:104
作者
Briles, DE
Hollingshead, SK
Nabors, GS
Paton, JC
Brooks-Walter, A
机构
[1] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35294 USA
[3] Aventis Pasteur, Swiftwater, PA USA
[4] Womens & Childrens Hosp, Mol Biol Unit, Adelaide, SA, Australia
关键词
PspA; PsaA; Streptococcus pneumoniae;
D O I
10.1016/S0264-410X(00)00285-1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Potential vaccine strategies against otitis media are to prevent (I) symptomatic infections in the middle ear and/or (2) carriage of pneumococci and thereby subsequent middle ear infections. The possibility of using immunity to virulence proteins of pneumococci to elicit immunity against pneumococci has been examined. PspA, has been found to have efficacy against otitis media in animals. Vaccination with a mixture of PsaA and PspA has been observed to offer better protection against nasal carriage in mice, than vaccination with either protein alone. PspA and pneumolysin have been shown to elicit protection against invasive infections. The inclusion of a few of these proteins into the polysaccharide-protein conjugate vaccines may be able to enhance their efficacy against otitis media and might be able to constitute a successful all-protein pneumococcal vaccine. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:S87 / S95
页数:9
相关论文
共 34 条
[21]   PSPA, A SURFACE PROTEIN OF STREPTOCOCCUS-PNEUMONIAE, IS CAPABLE OF ELICITING PROTECTION AGAINST PNEUMOCOCCI OF MORE THAN ONE CAPSULAR TYPE [J].
MCDANIEL, LS ;
SHEFFIELD, JS ;
DELUCCHI, P ;
BRILES, DE .
INFECTION AND IMMUNITY, 1991, 59 (01) :222-228
[22]   Current options for vaccine delivery systems by mucosal routes [J].
Mestecky, J ;
Moldoveanu, Z ;
Michalek, SM ;
Morrow, CD ;
Compans, RW ;
Schafer, DP ;
Russell, MW .
JOURNAL OF CONTROLLED RELEASE, 1997, 48 (2-3) :243-257
[23]  
NABORS GS, VACCINE, V189, P1743
[24]   Carriage of pneumococci after pneumococcal vaccination [J].
Obaro, SK ;
Adegbola, RA ;
Banya, WAS ;
Greenwood, BM .
LANCET, 1996, 348 (9022) :271-272
[25]  
OGUNNIYI AD, IN PRESS INFECT IMMU, V68
[26]   Novel pneumococcal surface proteins: role in virulence and vaccine potential [J].
Paton, JC .
TRENDS IN MICROBIOLOGY, 1998, 6 (03) :85-87
[27]   A comprehensive genetic study of streptococcal immunoglobulin A1 proteases: Evidence for recombination within and between species [J].
Poulsen, K ;
Reinholdt, J ;
Jespersgaard, C ;
Boye, K ;
Brown, TA ;
Hauge, M ;
Kilian, M .
INFECTION AND IMMUNITY, 1998, 66 (01) :181-190
[28]   Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice [J].
Tart, RC ;
McDaniel, LS ;
Ralph, BA ;
Briles, DE .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (02) :380-386
[29]  
Vakil M, 1991, Dev Immunol, V1, P203, DOI 10.1155/1991/45352
[30]   Effects of active immunization with a pneumococcal surface protein (PspA) and of locally applied antibodies in experimental otitis media [J].
White, P ;
Hermansson, A ;
Svanborg, C ;
Briles, D ;
Prellner, K .
ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY AND ITS RELATED SPECIALTIES, 1999, 61 (04) :206-211